Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled trial of glutamine to prevent oral mucositis and radiodermatitis in head and neck cancer patients
2009-018103-40Phase 2Active
- Sponsor
- David López Vaquero
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC), stomatitis and radiodermatitis comparing Glutamine with Placebo (2 arms). Primary endpoint: Primary: Grade of oral mucositis and radiodermatitis at 6 weeks of treatment. Started Apr 2010; status: active.
02
Drugs
glutamine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)stomatitisradiodermatitis
Beyond the preview
Go deeper on 2009-018103-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018103-40.